Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision
Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.
How this was made

The 30-second read
Why it matters
The key trading angle is whether the FDA has already indicated no greater cardiovascular risk versus auto-injectors, which can improve approval odds and reduce tail-risk. However, the company still lacks the exact rationale for observed blood-pressure response differences and expects post-marketing real-world evidence commitments after approval.
Market read
Regulatory risk framing and launch planning details can shift probability-weighting for approval, but the absence of a pricing decision and reliance on post-marketing evidence limit near-term certainty.
What to watch
No Anaphylm pricing is set, insurer discussions are preliminary, and the company’s sales plan depends on payer acceptance and real-world evidence design after approval.
Background
Aquestive is developing Anaphylm, a needle-free epinephrine film intended to treat severe allergic reactions, and is outlining clinical and regulatory expectations ahead of a 2027 FDA decision.
Ticker impact
Aquestive discusses Anaphylm clinical absorption and blood-pressure effects, plus FDA-written guidance on cardiovascular risk, shaping the 2027 decision outlook.
Shares may see modest upside bias as the market weighs reduced cardiovascular-risk concerns, tempered by remaining unanswered clinical-rationale questions.
The article provides specific FDA-related statements and trial preference/PK timing, but it does not report an approval, new endpoint, or a fresh regulatory milestone beyond expectations.
Market effects
Highlights competitive pressure in severe allergic reaction therapeutics and needle-free delivery, potentially affecting sentiment toward other epinephrine delivery platforms.
US launch planning and Canada/Europe/UK filing timelines may influence regional biotech/rare-allergy investor positioning.
Cross-region regulatory filing cadence (Canada, Europe, UK) can affect global expectations for needle-free epinephrine adoption.
Counterpoint
The article emphasizes theories and pending post-marketing commitments, so the FDA cardiovascular reassurance may not eliminate residual efficacy or safety concerns that could delay approval.
Key entities
- companyAquestive Therapeutics
NASDAQ-listed developer of PharmFilm drug-delivery technology, including Anaphylm for severe allergic reactions.
- productAnaphylm
Needle-free allergy treatment film discussed with absorption timing and blood-pressure response comparisons to auto-injectors.
- companyEton Pharmaceuticals
Partner mentioned for Libervant in the U.S.
- productLibervant
Diazepam buccal film for seizure clusters, described as tentatively approved and awaiting orphan exclusivity expiration.

